Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System

E-ISSN： 1873-4286|18|29|4570-4582

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.18, Iss.29, 2012-01, pp. : 4570-4582

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Animal Models of Central Nervous System Immune-Mediated Diseases: Therapeutic Interventions with Bioactive Peptides and Mimetics

Current Medicinal Chemistry, Vol. 12, Iss. 13, 2005-06 ,pp. : 1513-1519

Bentham Science Publishers

Access to resources Recommend Favorite

Cetuximab: Chronic immune-mediated demyelinating polyneuropathy: case report

Reactions Weekly, Vol. 1, Iss. 1332, 2010-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Biologics in Inflammatory Immune-mediated Systemic Diseases

Current Pharmaceutical Biotechnology, Vol. 18, Iss. 12, 2018-03 ,pp. : 1008-1016

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-inflammatory Activity of Extra Virgin Olive Oil Polyphenols: Which Role in the Prevention and Treatment of Immune-Mediated Inflammatory Diseases?

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 18, Iss. 1, 2017-12 ,pp. : 36-50

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy

By Ahmed A Razzaque

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 8, 2004-08 ,pp. : 1019-1032

Informa Healthcare

Access to resources Recommend Favorite